Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Adagene, Exelixis amend license agreement to develop third masked mAb

Adagene (NASDAQ: ADAG) has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate...

September 16, 2025

Executive Moves

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO. With more than 25 years of strategic and operational experience across...

September 16, 2025

Developments

Actinogen, FDA agree on activities toward marketing approval of Xanamem for AD

Actinogen Medical (ASX: ACW) has announced that an agreement with the FDA has been reached in a scheduled Type C meeting on the manufacturing, clinical, and nonclinical activities required for a future US marketing...

September 16, 2025

Developments

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Entera Bio (NASDAQ: ENTX) has announced the presentation of a poster highlighting pharmacokinetic data relating to its first-in-class oral GLP-2 analog program for the treatment of short bowel syndrome (SBS), at the...

September 16, 2025

Executive Moves

ALX appoints Dr. Barbara Klencke as interim CMO

ALX Oncology Holdings (NASDAQ: ALXO) has announced the appointment of board member Barbara Klencke, MD, as interim chief medical officer, (CMO). According to ALX, Dr. Alan Sandler is departing from the role of CMO and...

September 12, 2025

Developments

Cocrystal showcases potential first oral antiviral for norovirus

Cocrystal Pharma (NASDAQ: COCP) has announced that the scientific foundation and clinical progress of its lead pan-viral protease inhibitor, CDI-988, was discussed by President and CEO, Dr. Sam Lee, in a presentation at...

September 12, 2025

Developments

Karyopharm completes enrollment of Phase 3 SENTRY trial in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients. According...

September 10, 2025

Developments

BioXcel announces positive topline data for BXCL501 in bipolar and schizophrenia

BioXcel Therapeutics (NASDAQ: BTAI) has announced positive topline exploratory efficacy data from its SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 (IGALMI) for agitation associated with bipolar disorders or...

September 10, 2025

Developments

FDA grants Greenwich fast track designation for GLSI-100

Greenwich LifeSciences (NASDAQ: GLSI) announced that the FDA has granted GLSI-100 fast track designation for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment...

September 10, 2025

Executive Moves

MedX appoints Dr. Paul Matts as strategic advisor

MedX Health (TSXV: MDX) has announced the appointment of Dr. Paul J. Matts, internationally recognized skin scientist, biochemist, and educator, as strategic advisor. Dr. Matts is an academic and industry leader, as...

September 9, 2025

Developments

Perimeter Joins ASBrS Industry Relations Council

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it has joined the American Society of Breast Surgeons (ASBrS) Industry Relations Council (IRC). The ASBrS is the primary leadership organization for...

September 8, 2025

Developments

iMDX launches novel registry database; reports positive strategic update

Insight Molecular Diagnostics (iMDX) (NASDAQ: IMDX) has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant...

September 8, 2025

Subscribe